News about Drug Discovery & Development

Alembic Pharma Gets Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent (OTC) has an estimated market size of USD 22 million for twelve months.

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  390

Eugia Pharma Gets FDA Approval for Pazopanib Tablets

Aurobindo Pharma has announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg.

Drug Discovery & Development | 06/12/2024 | By Aishwarya |  323

KBI Biopharma Signs Manufacturing Contract with Alanis Therapeutics

As part of this collaborative agreement, KBI will oversee cell line development, process optimization, analytical and formulation development, and the manufacturing of Alanis’ pre-clinical antagonistic antibody (mAb).

Drug Discovery & Development | 04/12/2024 | By Aishwarya |  389

Lupin Gets Tentative Approval from FDA for Sitagliptin and Metformin Hydrochloride Tablets

Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Drug Discovery & Development | 02/12/2024 | By Aishwarya |  687

VectorBuilder Signs Deal with Sartorius to Advance Biopharmaceutical Innovation

The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.

Drug Discovery & Development | 29/11/2024 | By Aishwarya |  310

Glenmark Rolls Out Travoprost Ophthalmic Solution

Glenmark’s Travoprost Ophthalmic Solution USP, 0.004 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004 percent of Sandoz, Inc.

Drug Discovery & Development | 27/11/2024 | By Aishwarya |  333

Boehringer Ingelheim Unveils VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.

Drug Discovery & Development | 25/11/2024 | By Aishwarya |  378

Dr. Jitendra Singh Announces Soft Launch of Antibiotic Nafithromycin

The antibiotic ‘Nafithromycin’ has been developed with the support of Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology and has been brought to market under the trade name ‘Miqnaf’ by pharma company ‘Wolkardt’.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  935

Lupin Introduces Bumetanide Injection in US

Bumetanide Injection USP, is a generic equivalent of Bumex Injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  386

Alloy Therapeutics Signs License Deal with Takeda to Develop Cell Therapy Platform

Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications.

Drug Discovery & Development | 21/11/2024 | By Aishwarya |  312